We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye d... LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.38 | 14.3891017454 | 23.49 | 28.66 | 22.64 | 348813 | 27.52283383 | CS |
| 4 | 0.52 | 1.9734345351 | 26.35 | 28.66 | 16.535 | 323904 | 23.24464928 | CS |
| 12 | 1.19 | 4.63395638629 | 25.68 | 28.66 | 16.535 | 221766 | 23.89191195 | CS |
| 26 | 1.87 | 7.48 | 25 | 38.93 | 16.535 | 186857 | 26.60925165 | CS |
| 52 | 11.15 | 70.9287531807 | 15.72 | 38.93 | 14.42 | 182477 | 23.38945934 | CS |
| 156 | 10.89 | 68.1476846058 | 15.98 | 38.93 | 14.42 | 176534 | 23.17804571 | CS |
| 260 | 10.89 | 68.1476846058 | 15.98 | 38.93 | 14.42 | 176534 | 23.17804571 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
